Kiromic BioPharma, Inc. (KRBP) announced on Wednesday positive safety, tolerability, and early efficacy results for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial.
At the six-week mark, patients with stage 4 metastatic non-small cell lung cancer (NSCLC), who had previously not responded to standard therapies, exhibited disease stabilization, no new metastatic sites, and an 8.5% reduction in tumor size. The study also highlighted improvements in patients' quality of life.
Deltacel, an investigational gamma delta T-cell therapy, is currently undergoing evaluation in the Deltacel-01 Phase 1 trial for the treatment of stage 4 metastatic NSCLC.
